Randomized trial of early versus delayed GM-CSF with Campath-1H: Preliminary feasibility and correlative biologic studies results.

被引：0
|
作者：
Flinn, IW
Sickler, J
Lucas, M
Buj, V
Waymer, S
Shinn, C
Shabooti, M
Flynn, J
Diehl, L
Byrd, JC
机构：
[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA
[2] Walter Reed Army Med Ctr, Washington, DC 20307 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3622
引用
收藏
页码：838A / 838A
页数：1
相关论文
共 11 条
  • [1] Pancreas transplantation under campath-1H induction and tacrolimus monotherapy: Preliminary results.
    Thai, NL
    Khan, A
    Basu, A
    Tom, K
    Marcos, A
    Starzl, TE
    Shapiro, R
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 266 - 266
  • [2] Use of GM-CSF in pulmonary tuberculosis patients: preliminary results of a randomized clinical trial
    Pedral-Sampaio, DB
    Netto, EM
    Bandeira, AC
    Guerra, C
    Barberino, MG
    Hayes, A
    Badaro, R
    Agosti, J
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 312 - 312
  • [3] Alemtuzumab (campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial
    Margreiter, R.
    Klempnauer, J.
    Neuhaus, P.
    Muehlbacher, F.
    Boesmueller, C.
    Calne, R. Y.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (07) : 1480 - 1485
  • [4] USE OF GM-CSF (LEUKINE(R) SARGRAMOSTIM) AS A CHEMOPROTECTANT PRIOR TO IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE - PRELIMINARY-RESULTS OF A RANDOMIZED, CONTROLLED TRIAL
    PERKINS, JB
    FIELDS, KK
    ELFENBEIN, GJ
    BALLESTER, OF
    GOLDSTEIN, SC
    HIEMENZ, JW
    ZORSKY, PE
    BLOOD, 1994, 84 (10) : A585 - A585
  • [5] Alemtuzumab (Campath-1H) Induction Followed by Tacrolimus Monotherapy after Combined Kidney-Pancreas Transplantation: Results of a Prospective Randomized Trial
    Boesmueller, C.
    Sieb, M.
    Oellinger, R.
    Weissenbacher, A.
    Schneeberger, S.
    Pratschke, J.
    Margreiter, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 263 - 263
  • [6] Alemtuzumab (Campath-1H) Induction Followed by Tacrolimus Monotherapy after Combined Kidney-Pancreas Transplanation: Results of a Prospective Randomized Trial
    Boesmueller, C.
    Sieb, M.
    Oellinger, R.
    Weissenbacher, A.
    Schneeberger, S.
    Pratschke, J.
    Margreiter, R.
    TRANSPLANTATION, 2012, 94 (10) : 680 - 680
  • [7] A phase Ii study of the efficacy and toxicity of Campath-1H (anti-Cd52) for the therapy of adult T cell leukemia (Atl): Early results.
    Morris, JC
    O'Mahony, D
    Lee, CC
    O'Hagan, D
    Wendy, G
    Waldmann, TA
    Janik, JE
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (05) : 446 - 446
  • [8] Primary analysis of the prospective, randomized, phase trial of GP2H-GM-CSF Vacilne versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients
    Schneble, Erika J.
    Perez, Sonia A.
    Murray, James L.
    Berry, John S.
    Trappey, Alfred F.
    Vreeland, Timothy J.
    Hale, Diane F.
    Greene, Julia M.
    Clifton, Guy T.
    Ardavanis, Alexandros
    Litton, Jennifer Keating
    Ponniah, Sathibalan
    Shumway, Nathan M.
    Papamichail, Michael
    Peoples, George Earl
    Mittendorf, Elizabeth Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [9] Preliminary results of a phase 1 clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients
    Head, Jonathan F.
    Daniels, Gregory A.
    McKinney, Michelle
    Ongkeko, Weg
    Sakamoto, Kyoko
    Wang-Rodriguez, Jessica
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [10] A phase I/II randomized trial using GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) vaccine in combination with CCL21 in stage IV lung adenocarcinoma: Preliminary results.
    Gray, Jhanelle Elaine
    Chiappori, Alberto
    Williams, Charles C.
    Pinder, Mary Colleen
    Haura, Eric B.
    Kim, Jongphil
    Gonzalez, Germaine
    Noyes, David
    Antonia, Scott J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12